News | Structural Heart Occluders | May 05, 2022

Surgeons Use Novel Occluder with a Metal-Free Frame on a Patient with ASD

The novel device has been implanted as part of the ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial.

reSept ASD Occluder

The reSept ASD Occluder is the first transcatheter ASD occluder with a metal-free frame.


May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial septal defects (ASD), or opening defect in the wall of the heart that separates the top two chambers of the heart, using the first transcatheter ASD occluder with a metal-free frame. The novel device has been implanted as part of the ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial, which will evaluate the safety and efficacy of the transcatheter reSept ASD Occluder in patients with clinically significant secundum ASDs. It was the hospital’s first patient with ASD enrolled in this trial.

Dr. Larry Latson, Joe DiMaggio Children's Hospital Heart InstituteDr. Larry Latson, MD, Medical Director, Pediatric & Congenital Interventional Cardiology Program Co-Medical Director, Adult Congenital Heart Disease Program at Joe DiMaggio Children’s Hospital is National Co-Principal Investigator for this study, and part of the pediatric cardiac team that performed the transcatheter procedure. The prospective, single-arm study will enroll up to 250 patients at multiple sites globally Primary endpoints will be compared with established performance goals for previously FDA-approved transcatheter ASD occluders.

“We are pleased to be part of this global study and provide an innovative treatment to our pediatric patients who are suffering from this condition here in South Florida,” Dr. Latson said. “With studies of this kind and world-wide collaboration, we are able to give our patients access to the most innovative treatments that will transform the way we treat congenital heart disease in the future.”

Current ASD occluders have metallic frames that could place patients at risk for complications associated with long-term presence of metal in the heart and may limit future transseptal interventions. Initial clinical experience demonstrates effective closure of the ASDs treated with the novel investigational device.1

“The metal-free frame of the reSept ASD Occluder provides a low-profile that over time is replaced by the patient’s tissue, leaving a minimal implant behind and restoring a more natural septum when compared to current occluder devices,” stated Saibal Kar, MD, Interventional Cardiology at the Los Robles Regional Medical Center in Thousand Oaks, California and Co-Principal Investigator of the IDE trial. “This provides a unique opportunity for physicians to effectively address ASDs while being mindful of any patient’s potential transseptal procedures later in life.”

The reSept ASD Occluder is the first transcatheter ASD occluder with a metal-free frame. It is an investigational medical device manufactured by atHeart Medical.

“It is incredibly exciting to have the participation of Joe DiMaggio Children’s Hospital to this important pivotal trial,” said Laurent Grandidier, CEO of atHeart Medical. “I commend the team’s diligence to expanding the body of evidence supporting our reSept ASD Occluder and dedication to delivering innovation to patients with ASDs around the world."

Reference:
1. Sievert K, et al. Transcatheter closure of atrial septal defect and patent foramen ovale with Carag bioresorbable septal occluder: first-in-man experience with 24-month follow-up. EuroIntervention. 2021 Nov 1:EIJ-D-21-00740. doi: 10.4244/EIJ-D-21-00740. Epub ahead of print. PMID: 34726601. 


Related Content

News | Pediatric Cardiology

November 25, 2022 — Jodie Votava-Smith, MD, has pulled up two side-by-side echocardiograms on her computer screen and is ...

Home November 25, 2022
Home
News | Pediatric Cardiology

November 23, 2022 — Cardiopulmonary exercise testing (CPET) can detect underlying early signs of cardiovascular problems ...

Home November 23, 2022
Home
News | Pediatric Cardiology

November 14, 2022 — For more than four decades, doctors have been split on whether giving steroids during a pediatric ...

Home November 14, 2022
Home
News | Pediatric Cardiology

October 27, 2022 — Elite young athletes are set to benefit from a novel screening tool with the potential to change ...

Home October 27, 2022
Home
News | Pediatric Cardiology

September 28, 2022 — Babies born with heart valve defects will have as many as 3 to 5 open heart surgeries before ...

Home September 28, 2022
Home
News | Pediatric Cardiology

September 20, 2022 — Medtronic, a global leader in healthcare technology, today announced the LINQ II Insertable Cardiac ...

Home September 20, 2022
Home
News | Pediatric Cardiology

July 13, 2022 — Black children who underwent heart transplant surgery for the first time were more than three times as ...

Home July 13, 2022
Home
News | Pediatric Cardiology

July 1, 2022 — Most children and adolescents living in the U.S. have suboptimal scores for cardiovascular health (CVH) ...

Home July 01, 2022
Home
News | Pediatric Cardiology
April 18, 2022 – Deepening its commitment to pediatric cardiovascular research, the Children's Hospital of Philadelphia ...
Home April 18, 2022
Home
News | Pediatric Cardiology
March 2, 2022 – As 1-year-old SaRyia Moore and her family celebrate American Heart Month, they do so will full, grateful ...
Home March 02, 2022
Home
Subscribe Now